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Abstract
Background: SPINK1 (serine protease inhibitor, kazal-type, 1), which encodes human pancreatic secretory trypsin
inhibitor, is one of the most extensively studied genes underlying chronic pancreatitis. Recently, based upon data
from qualitative reverse transcription-PCR (RT-PCR) analyses of transfected HEK293T cells, we concluded that 24
studied SPINK1 intronic variants were not of pathological significance, the sole exceptions being two canonical
splice site variants (i.e., c.87 + 1G > A and c.194 + 2T > C). Herein, we employed the splicing prediction tools included
within the Alamut software suite to prioritize the ‘non-pathological’ SPINK1 intronic variants for further quantitative
RT-PCR analysis.
Results: Although our results demonstrated the utility of in silico prediction in classifying and prioritizing intronic
variants, we made two observations worth noting. First, we established that most of the prediction tools employed
ignored the general rule that GC is a weaker donor splice site than the canonical GT site. This finding is potentially
important because for a given disease gene, a GC variant donor splice site may be associated with a milder clinical
manifestation. Second, the non-pathological c.194 + 13T > G variant was consistently predicted by different programs
to generate a new and viable donor splice site, the prediction scores being comparable to those for the physiological
c.194 + 2T donor splice site and even higher than those for the physiological c.87 + 1G donor splice site. We do
however provide convincing in vitro evidence that the predicted donor splice site was not entirely spurious.
Conclusions: Our findings, taken together, serve to emphasize the importance of functional analysis in helping to
establish or refute the pathogenicity of specific intronic variants.
Keywords: Aberrant mRNA transcripts, Chronic pancreatitis, In silico, Intronic variants, Non-canonical splice sites,
Quantitative RT-PCR analysis, SPINK1, Splicing phenotype prediction
Background
SPINK1 (serine protease inhibitor, kazal-type, 1; OMIM
#167790), which encodes pancreatic secretory trypsin in-
hibitor, is one of the most extensively studied genes
underlying chronic pancreatitis [1]. Of the some 90 dif-
ferent nucleotide sequence variants listed in the Chronic
Pancreatitis Genetic Risk Factors Database (http://
www.pancreasgenetics.org/index.php; accessed 2 Jan 2017),
31 (34%) are intronic, a difficult category of sequence
variant to ascertain in terms of their potential patho-
logical relevance. Recently, using a ‘maxigene’ expression
assay for which the full-length SPINK1 genomic
sequence (approximately 7 kb stretching from the
translational initiation codon to the stop codon of the
four-exon gene) was cloned into the pcDNA3.1/V5-His-
TOPO vector, we analyzed the functional consequences
of 24 SPINK1 intronic variants for the mRNA splicing
phenotype in transfected HEK293T cells by means of
reverse transcription-PCR (RT-PCR) analysis. Based
upon the observed splicing patterns, we concluded that
none of the studied variants, apart from the two
canonical splice site variants (i.e., c.87 + 1G > A and
c.194 + 2T > C), were of pathological significance [2, 3].
However, upon reflection, we felt that whereas our
conclusions regarding the two canonical splice site
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variants were solid, those relating to the other 22 in-
tronic variants could have been too hasty. For example,
some of these 22 intronic variants might have caused
aberrant splicing albeit to a limited extent. However,
such aberrantly spliced transcripts may have been rap-
idly degraded by the cellular mRNA quality control sys-
tem as compared with the correctly spliced transcripts,
resulting in a quantitative decrease in terms of the cor-
rectly spliced transcripts. To explore this possibility, we
employed the commonly used in silico splicing predic-
tion programs to prioritize these SPINK1 intronic vari-
ants for further quantitative RT-PCR analysis.
Materials and methods
In silico splicing prediction
All 24 of the SPINK1 intronic variants previously analyzed
by the maxigene assay [2, 3] were re-examined in the con-
text of in silico splicing prediction by means of Alamut®
Visual version 2.7.1 (Interactive Biosoftware, Rouen,
France) that included five prediction algorithms viz.
SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSpli-
cer, and Human Splicing Finder. We focused exclusively
on the potential impact of the SPINK1 intronic variants in
terms of the disruption of known splice sites or the
creation of new potential splice sites. We firstly used data
derived from the two canonical splice site variants (i.e.,
c.87 + 1G >A and c.194 + 2T > C) as a first means to as-
sess the performance of each of the five prediction pro-
grams. We then used the selected programs to prioritize
variants for quantitative RT-PCR analysis.
Quantitative RT-PCR analysis of four prioritized variants in
the context of a maxigene assay
Four variants (i.e., c.87 + 363A > G, c.194 + 13T > G,
c.194 + 1504A > G, and c.195-323C > T) were prioritized
for quantitative RT-PCR analysis. The wild-type and
variant expression vectors harboring the corresponding
full-length genomic SPINK1 genes have been previously
described [2, 3]. HEK293T cell culture, transfection, re-
verse transcription, and real-time quantitative RT-PCR
analyses were performed as described [4], except that
the primer pair used for amplifying the full-length
target gene transcripts was changed to 5′-GGAGACC
CAAGCTGGCTAGT-3′ (forward) and 5′-AGACC
GAGGAGAGGGTTAGG-3′ (reverse); the forward and
reverse primers are located within the pcDNA3.1 5′-
and 3′-untranslated regions, respectively (i.e., the
primer pair Q1 as described in [5]).
Further analyses of the c.194 + 13T > G variant in the
context of a maxigene assay
Analysis of nonsense-mediated mRNA decay (NMD)
This analysis was performed as described in [4], with the
CEL-HYB1 and CEL-HYB2a expression vectors being
replaced by the aforementioned full-length SPINK1 wild-
type and c.194 + 13T > G variant gene expression
vectors, respectively.
Identification of the in silico predicted aberrant transcript
The c.194 + 13T >G variant was consistently predicted by
the selected four programs to create a putative splice
donor site (see Results and discussion). An allele-specific
forward primer, 5′-ATGTTTTGAAAATCGGTGAG
TAC-3′, was used together with the reverse primer of the
aforementioned primer pair Q1 [5] to amplify this pre-
dicted aberrant transcript. The PCR program comprised
an initial denaturation at 95 °C for 15 min, followed by
35 cycles of denaturation at 94 °C for 45 s, annealing at
58 °C for 45 s, and extension at 72 °C for 1 min.
Estimation of the frequency of the aberrant transcripts
relative to the wild-type transcripts
Using the aforementioned primer pair Q1, we performed
RT-PCR to amplify the full-length transcripts prepared
from the c.194 + 13T > G variant maxigene-transfected
HEK293T cells treated with cycloheximide. After
addition of 3′-A overhangs, the purified products were
cloned into the pcDNA3.1/V5-His-TOPO vector
(Invitrogen, Carlsbad, CA, USA). Transformation was
performed using XL10-Gold Ultracompetent Cells
(Stratagene, La Jolla, CA, USA), and transformed cells
were spread onto LB agar plates with 50 mg/mL ampi-
cillin and were incubated at 37 °C overnight [4]. Bacter-
ial colonies were picked to be added into a 25 μl PCR
mixture, which contained 12.5 μl HotStarTaq Master
Mix (QIAGEN), 0.4 μM each primer (i.e., primer pair
C1 in [5]; the forward and reverse primer sequences are
located within the beginning and the end regions of the
SPINK1 coding sequence, respectively). The PCR had an
initial denaturation step at 95 °C for 15 min, followed by
30 cycles of denaturation at 94 °C for 45 s, annealing at
58 °C for 45 s, and extension at 72 °C for 45 s. The sam-
ples showing the expected band on the gel were cleaned
and sequenced using the forward primer.
Further analyses of the c.194 + 13T > G variant in the
context of a minigene assay
Minigene construction and mutagenesis
A 567-bp fragment spanning the exon 3 of SPINK1 as
well as 230 bp flanking intronic sequences on both
sides (Additional file 1) was amplified using primers 5′-
CGGGCCCCCCCTCGAGTTTCAGAAGGGCCATAG
GAC-3′ (forward) and 5′-TAGAACTAGTGGATCCC
CAAGCTATCGACTATTTTGCTG-3′ (reverse). PCR
was performed in a 25 μl reaction mixture containing
0.5 U KAPA HiFi HotStart DNA Polymerase, 5 μl 5×
KAPA HiFi Buffer, 0.75 μl dNTP Mix, 20 ng expression
vector containing the full-length wild-type SPINK1
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genomic sequence [5], and 0.3 μM each primer. The PCR
program comprised an initial denaturation at 95 °C for
5 min followed by 30 cycles of denaturation at 98 °C for
20 s, annealing at 66 °C for 15 s, extension at 72 °C for
15 s, and a final extension at 72 °C for 5 min. The PCR
products were cloned into the Exontrap vector pET01
(MoBiTec) that was linearized by restriction enzymes
BamHI and XhoI, using the In-Fusion® HD Cloning kit
(Clontech) in accordance with the manufacturer’s instruc-
tions. The resulting expression vector was termed the
wild-type SPINK1 exon 3 minigene.
The c.194 + 13T > G variant was introduced into the
wild-type SPINK1 exon 3 minigene as previously
described for introducing the same variant into the wild-
type SPINK1 maxigene vector [2], except that the exten-
sion time was reduced from 13 to 5 min. The successful
introduction of the variant was confirmed by DNA
sequencing using primers 5′-GTAGCTGCCAGGAAG
GAGTG-3′ (forward) and 5′-GGCCTCCAAAACCTA
CACAT-3′ (reverse).
Qualitative and quantitative RT-PCR analyses
HEK293T cell culture, transfection, and reverse transcrip-
tion were performed as previously described [2]. Qualita-
tive RT-PCR was performed in a 25 μl mixture containing
12.5 μl HotStarTaq Master Mix (QIAGEN), 0.4 μM each
primer (5′-GAGGGATCCGCTTCCTGGCCC-3′ (for-
ward) and 5′-CTCCCGGGCCACCTCCAGTGCC-3′ (re-
verse)), and 1 μl cDNA. The program had an initial
denaturation at 95 °C for 15 min followed by 30 cycles of
denaturation at 94 °C for 45 s, annealing at 58 °C for 45 s,
and extension at 72 °C for 2 min. PCR products were
cleaned by ExoSAP-IT (Affymetrix) and were sequenced
using a BigDye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems).
Quantitative RT-PCR analysis was done as previously
described [4], except that the primers used for target
gene amplification were changed to those used for the
aforementioned qualitative RT-PCR analysis.
Results and discussion
The increasingly routine use of whole genome sequen-
cing has led to the discovery of an increasing number of
rare variants, particularly intronic variants, owing to the
relatively large size of intronic sequences as compared to
the exonic sequences of protein-coding genes. It is, in
practice, generally unrealistic to functionally analyze the
large number of intronic variants detected in protein-
coding genes. In silico prediction is therefore commonly
used both to classify and prioritize intronic variants for
further functional analysis [6, 7]. Herein, we adopted this
approach to prioritize SPINK1 intronic variants, which
had been previously classified as ‘non-pathological’ in ac-
cordance with data obtained from qualitative RT-PCR
analyses of transfected HEK293T cells [2, 3], for further
quantitative analysis. To this end, we predicted the im-
pact on mRNA splicing of all 24 previously functionally
analyzed SPINK1 intronic variants by means of the
widely used Alamut software suite, focusing on their po-
tential disruption or creation of splice sites in accord-
ance with previous studies [7, 8]. The corresponding
score changes for each variant, predicted by each of the
five prediction programs included within Alamut, are
summarized in Additional file 2.
Using data from two canonical splice site variants as a
first means to assess the relative performance of the five
splicing prediction programs
There are currently no consensus guidelines as to which
prediction tools should be used or how the results of
predictions should be interpreted [9]. Importantly, of the
24 SPINK1 intronic variants studied here, c.87 + 1G > A
and c.194 + 2T > C affected canonical splice donor splice
sites and were the only tested variants that had been
previously shown to result in aberrant splicing using a
maxigene assay [2, 3]. We therefore used data from
these two variants as a means to assess the relative per-
formance of the five splicing prediction programs
included within the Alamut software suite.
GeneSplicer was excluded from consideration owing to its
poor performance in relation to the two corresponding
wild-type alleles
We first assessed the relative performance of the five
splicing prediction programs by evaluating their
prediction scores with respect to the corresponding
wild-type alleles of the two canonical splice site vari-
ants. SpliceSiteFinder-like, MaxEntScan, NNSPLICE,
and Human Splicing Finder all yielded scores that were
≥79.8% of their respective maxima. However, GeneSpli-
cer only yielded a score of <27% of its maximum
(Additional file 3) and was therefore excluded from
further consideration.
A particular observation with respect to the c.194 + 2T > C
variant
We then correlated the prediction scores from the four
selected programs and the known splicing phenotypes
in relation to the two canonical splice site variant
alleles. In the context of the c.87 + 1G > A variant allele,
SpliceSiteFinder-like, MaxEntScan, NNSPLICE, and
Human Splicing Finder all predicted a score of zero
(Table 1). This prediction was consistent with the
complete exon 2 skipping that was observed in the
maxigene assay [2].
A particular observation was made in the context of
the c.194 + 2T > C variant. This variant was shown to
lead to two distinct transcripts, one wild-type, the other
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lacking exon 3, the aberrant transcript being expressed
at a much higher level than the wild-type transcript in
our maxigene assay [2]. These results not only concur
with those obtained from the analysis of mRNA derived
from stomach tissue (in which SPINK1 is also abun-
dantly expressed) from a c.194 + 2T > C homozygote
[10] but are also consistent with the general rule that
GC is a lesser frequently used and weaker splice donor
site as compared to the canonical GT site [11, 12]. How-
ever, only SpliceSiteFinder-like predicted a consistent
reduced score (from 82.6 to 72.3) whilst MaxEntScan,
NNSPLICE, and Human Splicing Finder all predicted a
score of zero (Table 1).
Taken together, in the context of the two canonical
splice site variants, a good correlation was noted between
the predictions of SpliceSiteFinder-like, MaxEntScan,
NNSPLICE, and Human Splicing Finder and the in vitro
maxigene-obtained functional results, although only
SpliceSiteFinder-like yielded a perfect correlation in
both cases.
In silico prioritization of the 22 ‘non-pathological’ variants
for further quantitative analysis
We classified the 22 empirically tested ‘non-pathological’
SPINK1 intronic variants into three categories in accord-
ance with the predictions by SpliceSiteFinder-like,
MaxEntScan, NNSPLICE, and Human Splicing Finder
(Additional file 2).
Category 1 comprised 13 variants, none of which were
predicted to affect splicing by any of the four programs.
These variants were excluded from further functional
analysis.
Category 2 comprised three variants that were only
predicted (and only by Human Splicing Finder) to
disrupt a putative splice acceptor or donor site (i.e.,
c.88-352A > G, c.194 + 90A > T, and c.194 + 184 T > A).
These predictions were clearly inappropriate because (i)
the SPINK1 gene is not known to have alternative tran-
scripts and (ii) we did not observe any alternative tran-
scripts from the wild-type SPINK1 gene in the maxigene
assay. They were therefore also excluded from further
functional analysis.
Category 3 comprised 6 variants, each being predicted
by at least one program to create a new donor or acceptor
splice site. Of these, c.194 + 13T >G was predicted by all
four programs to create a potential donor splice site and
both c.194 + 1504A >G and c.195-323C > T were pre-
dicted by three of the four programs to create a potential
donor splice site. These three variants were selected for
further functional analysis (Table 1).
The remaining three category 3 variants were all
predicted by one and the same program (i.e., Human
Splicing Finder) to create a new donor or acceptor
splice site (i.e., c.87 + 363A > G, c.195-1570C > A, and
c.195-1399G > A). Of these, we selected that which had
the highest predicted score (i.e., 83.3 of the maximum
score of 100; c.87 + 363A > G), for further analysis
(Table 1).
All four prioritized variants were not found to
significantly reduce mRNA expression by quantitative RT-
PCR analysis
We performed quantitative RT-PCR analysis of the
HEK293T cells co-transfected with each of the expres-
sion vectors harboring the respective full-length
variant SPINK1 genes and the reference PGL3-GP2
plasmid [4, 5]. We did not however observe statisti-
cally significant differences in mRNA expression level
between any of the four variants and the wild-type
(Fig. 1).
Further analyses of the c.194 + 13T > G variant
Of the four variants subjected to quantitative RT-PCR
analysis, c.194 + 13T > G was the only one that was
Table 1 In vitro observed and in silico predicted mRNA splicing phenotypes associated with the two canonical splice site variants
and four intronic variants prioritized for quantitative RT-PCR analysis
Intron SPINK1 variant SpliceSiteFinder-like
(0–100)
MaxEntScan
(0–12)
NNSPLICE
(0–1)
Human Splicing Finder
(0–100)
In vitro observed mRNA
splicing phenotypea
Canonical splice donor site variants
2 c.87 + 1G > A dss 79.8→ 0 dss 8.3→ 0 dss 0.9→ 0 dss 84.1→ 0 Complete exon 2 skipping
3 c.194 + 2T > C dss 82.6→ 72.3 dss 11.1→ 0 dss 1.0→ 0 dss 92.1→ 0 Partial exon 3 skipping
Variants prioritized for quantitative RT-PCR analysis
2 c.87 + 363A > G − − − dss 0→ 65.5 Normal
ass 0→ 83.3
3 c.194 + 13T > G dss 0→ 82.0 dss 0→ 9.5 dss 0→ 0.9 dss 0→ 86.9 Normal
3 c.194 + 1504A > G dss 0→ 77.2 − dss 0→ 0.7 dss 0→ 83.2 Normal
3 c.195-323C > T − dss 0→ 6.3 dss 0→ 0.7 dss 0→ 75.1 Normal
Abbreviations: dss donor splice site, ass acceptor splice site
aIn accordance with Zou et al. [2, 3]
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consistently predicted by the SpliceSiteFinder-like,
MaxEntScan, NNSPLICE, and Human Splicing Finder
programs to create a potential donor splice site, with
each program predicting a relatively high score (Table 1).
Indeed, the predicted scores for this variant were even
higher than, or at least equal to, the corresponding ones
for the physiological c.87 + 1G donor splice site (Table 1).
Moreover, the predicted scores for this variant were
comparable to those for the physiological c.194 + 2T
donor splice site (Table 1), the two sites being separated
by only 10 bp.
The use of the predicted splice donor site would lead to
the generation of an aberrant transcript containing a pre-
mature stop codon (Fig. 2a). Such a transcript might be
subject to significant degradation by NMD [13], leading to
a reduced mRNA expression level. In this regard, the
aforementioned quantitative RT-PCR analyses hinted at a
possible reduced level of expression of the correctly
spliced transcripts from the c.194 + 13T >G variant maxi-
gene (Fig. 1). To clarify this issue, we performed further
quantitative RT-PCR analysis of the c.194 + 13T >G vari-
ant maxigene-transfected HEK293T cells with or without
treatment with cycloheximide (a known NMD inhibitor
[14]) as previously described [4], but no statistically signifi-
cant changes were observed (Additional file 4).
Additionally, we analyzed the impact on splicing of the
c.194 + 13T >G variant in the context of a minigene assay.
We found only a single band whose size was similar to
that of the wild-type (Additional file 5a) and whose iden-
tity to the wild-type sequence was confirmed by sequen-
cing the RT-PCR product. We further performed
quantitative RT-PCR analysis of the HEK293T cells co-
transfected with the c.194 + 13T >G variant-containing
minigene expression vector and the PGL3-GP2 plasmid.
We did not observe statistically significant differences in
mRNA expression level between the c.194 + 13T >G vari-
ant and the wild-type (Additional file 5b).
We then speculated that such an aberrant transcript
might exist but at such an extremely low level as com-
pared to the correctly spliced transcript that it would
be beyond the detection limit of quantitative RT-PCR
analysis. We therefore designed an allele-specific for-
ward primer (rightward blue arrow in Fig. 2a) in an at-
tempt to detect this aberrant transcript if it were to
exist. Use of this forward primer and a reverse primer
located within the pcDNA3.1 3′-untranslated region
succeeded in detecting a specific RT-PCR product
from the c.194 + 13T > G variant maxigene-transfected
HEK293T cells (both with and without cycloheximide
treatment) but not in the wild-type SPINK1 maxigene-
transfected HEK293T cells (Fig. 2b). Sequencing of this
specific RT-PCR product confirmed the use of pre-
dicted novel splice donor site (Fig. 2c).
To obtain an approximate estimate of the expression
level of the aberrant transcript relative to the correctly
spliced transcript, we then performed colony PCRs
followed by sequencing of the full-length transcripts
amplified from the c.194 + 13T > G variant maxigene-
transfected HEK293T cells treated with cycloheximide.
Sequencing of 100 PCR products of expected size re-
vealed only wild-type transcript. [note that the wild-type
and aberrant transcripts are indistinguishable by gel ana-
lysis owing to their length difference of only 12 bp; see
Fig. 2a.] This suggested that the c.194 + 13T > G variant
resulted in less than 1% of aberrantly spliced transcripts
relative to the amount of wild-type transcript.
Conclusions
In silico prioritization and subsequent quantitative
RT-PCR analyses of selected SPINK1 intronic variants
for further functional characterization in a maxigene
assay supported our previous classification of 24
SPINK1 intronic variants as having pathological rele-
vance (or not) in chronic pancreatitis [2, 3]. As in
many studies, our results demonstrated the utility of
in silico prediction in classifying and prioritizing in-
tronic variants. However, we made two observations
worth noting during this study. First, we found that
most of the prediction programs included within the
commonly used Alamut software suite ignore the gen-
eral rule that GC is a weaker donor splice site as com-
pared with the canonical GT donor splice site. This
finding serves to remind us of a key point in medical
genetics: in a given disease gene, a C introduced into
the second position of a canonical GT donor splice site
may have a milder clinical manifestation than a G or A.
Fig. 1 Relative mRNA expression levels associated with four variant
SPINK1 gene constructs compared to that of the wild-type, as
determined by the quantitative RT-PCR analysis of HEK293T cells
transfected with various maxigene expression constructs. Results are
given as the mean ± SD from three independent transfection
experiments. No statistically significant difference in mRNA expression
level was noted between any of the variants and the wild-type
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Second, the non-pathological c.194 + 13T > G variant
was consistently predicted by the selected four pro-
grams to generate a potential donor splice site; the
prediction scores being even higher than the physio-
logical c.87 + 1G splice site. However, by means of
allele-specific PCR, we provided convincing in vitro
evidence that the predicted donor splice site was not
entirely spurious (Fig. 2). These findings, taken to-
gether, serve to emphasize the importance of func-
tional analysis in helping to establish or refute the
pathogenicity of certain intronic variants, an issue of
increasing importance in the new age of precision
medicine [15, 16]. This notwithstanding, it should be
pointed out that in the context of the c.194 + 13T > G
variant, it would be desirable to investigate its effect in
the corresponding carrier’s pancreatic tissue. However,
obtaining such a tissue sample would be extremely dif-
ficult particularly given that the c.194 + 13T > G vari-
ant has so far been reported only once [17].
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Abbreviations
ass: Acceptor splice site; dss: Donor splice site; NMD: Nonsense-mediated
mRNA decay; RT-PCR: Reverse transcription-PCR
Fig. 2 Confirmation of the Alamut-predicted creation of a new splice donor site by the SPINK1 c.194 + 13T > G variant. a Schemas for the
splicing of intron 3 with respect to the wild-type and variant alleles of c.194 + 13T > G. The splice donor (GT) and splice acceptor (AG)
signals potentiating the normal and aberrant splicing of intron 3 are highlighted in bold and underlined. The rightward pointing blue arrow
indicates the forward allele-specific primer designed to amplify the predicted aberrant transcript (as shown in b). The 12 bp intronic
sequence inappropriately included within the predicted aberrant transcript is indicated by a red box. The amino acid sequences of the
wild-type and predicted mutant proteins are also shown. b PCR identification of the aberrant transcripts expressed from the HEK293T cells
transfected with the c.194 + 13T > G variant-containing maxigene expression construct. The primers used for amplification were the forward
allele-specific primer as illustrated in (a) and a reverse primer located within the 3′ untranslated region of the expression vector. No PCR
products were identified in cells transfected with the wild-type maxigene expression vector. Plus and minus symbols refer to cells treated
with and without cycloheximide, respectively. c Sequence of the c.194 + 13T > G/+ PCR products as illustrated in (b). The 12 bp intronic
sequence included within the aberrant transcript is indicated by a red box
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